Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action.
Straub
Rainer H
RH
Laboratory of Experimental Rheumatology and Neuroendocrino-Immunology, Division of Rheumatology, Department of Internal Medicine I, University Hospital, 93042 Regensburg, Germany. rainer.straub@klinik.uni-regensburg.de
Härle
Peter
P
Sarzi-Puttini
Piercarlo
P
Cutolo
Maurizio
M
D000324:Adrenocorticotropic Hormone / Q000502:physiology; D000728:Androgens / Q000502:physiology; D000906:Antibodies / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D001341:Autonomic Nervous System / Q000502:physiology; D002490:Central Nervous System / Q000502:physiology; D006801:Humans; D006854:Hydrocortisone / Q000502:physiology; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology; D008099:Liver / Q000502:physiology; D009132:Muscles / Q000502:physiology; D009490:Neurosecretory Systems / Q000502:physiology*; D010913:Pituitary-Adrenal System / Q000502:physiology; D013583:Synovial Membrane / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000502:physiology*
D000728:Androgens; D000906:Antibodies; D014409:Tumor Necrosis Factor-alpha; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone